Author:
Yamano Akihiro,Inoue Tatsuya,Yagihashi Takayuki,Yamanaka Masashi,Matsumoto Kazuki,Shimo Takahiro,Shirata Ryosuke,Nitta Kazunori,Nagata Hironori,Shiraishi Sachika,Minagawa Yumiko,Omura Motoko,Tokuuye Koichi,Chang Weishan
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
2. Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 2013;5:S389–96.
3. Allen AM, Pawlicki T, Dong L, Fourkal E, Buyyounouski M, Cengel K, et al. An evidence-based review of proton beam therapy: the report of ASTRO’s emerging technology committee. Radiother Oncol. 2012;103:8–11.
4. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Eng J Med. 2018;379:2342–50.
5. Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65:1087–96.